Lenalidomide Patent Expiration

Lenalidomide is used for treating mantle cell lymphoma, multiple myeloma, and myelodysplastic syndromes. It was first introduced by Bristol Myers Squibb in its drug Revlimid on Dec 27, 2005. 17 different companies have introduced drugs containing Lenalidomide.

Lenalidomide Patents

Given below is the list of patents protecting Lenalidomide, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Revlimid	US8741929	Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas	Mar 08, 2028	Bristol Myers Squibb
Revlimid	US7465800	Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione	Apr 27, 2027	Bristol Myers Squibb
Revlimid	US7855217	Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione	Nov 24, 2024 (Expired)	Bristol Myers Squibb
Revlimid	US7468363	Methods for treatment of cancers using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione	Oct 07, 2023 (Expired)	Bristol Myers Squibb
Revlimid	US7968569	Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione	Oct 07, 2023 (Expired)	Bristol Myers Squibb
Revlimid	US8492406	Methods for treatment of follicular lymphoma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione	Oct 07, 2023 (Expired)	Bristol Myers Squibb
Revlimid	US8530498	Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione	May 15, 2023 (Expired)	Bristol Myers Squibb
Revlimid	US8648095	Methods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with proteasome inhibitor	May 15, 2023 (Expired)	Bristol Myers Squibb
Revlimid	US9101621	Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation	May 15, 2023 (Expired)	Bristol Myers Squibb
Revlimid	US9101622	Methods for treating newly diagnosed multiple myeloma 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with dexamethasone	May 15, 2023 (Expired)	Bristol Myers Squibb
Revlimid	US9155730	Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent	May 15, 2023 (Expired)	Bristol Myers Squibb
Revlimid	US9393238	Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent	May 15, 2023 (Expired)	Bristol Myers Squibb
Revlimid	US7189740	Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes	Apr 11, 2023 (Expired)	Bristol Myers Squibb
Revlimid	US8404717	Methods of treating myelodysplastic syndromes using lenalidomide	Apr 11, 2023 (Expired)	Bristol Myers Squibb
Revlimid	US9056120	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine	Apr 11, 2023 (Expired)	Bristol Myers Squibb
Revlimid	US6315720	Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug	Oct 23, 2020 (Expired)	Bristol Myers Squibb
Revlimid	US6561977	Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated	Oct 23, 2020 (Expired)	Bristol Myers Squibb
Revlimid	US6755784	Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated	Oct 23, 2020 (Expired)	Bristol Myers Squibb
Revlimid	US8315886	Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated	Oct 23, 2020 (Expired)	Bristol Myers Squibb
Revlimid	US8626531	Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated	Oct 23, 2020 (Expired)	Bristol Myers Squibb
Revlimid	US5635517	Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines	Oct 04, 2019 (Expired)	Bristol Myers Squibb
Revlimid	US5635517	Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines	Oct 04, 2019 (Expired)	Bristol Myers Squibb
Revlimid	US6045501	Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug	Aug 28, 2018 (Expired)	Bristol Myers Squibb
Revlimid	US6561976	Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug	Aug 28, 2018 (Expired)	Bristol Myers Squibb
Revlimid	US6908432	Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug	Aug 28, 2018 (Expired)	Bristol Myers Squibb
Revlimid	US8204763	Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug	Aug 28, 2018 (Expired)	Bristol Myers Squibb
Revlimid	US8589188	Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug	Aug 28, 2018 (Expired)	Bristol Myers Squibb
Revlimid	US6281230	Isoindolines, method of use, and pharmaceutical compositions	Jul 24, 2016 (Expired)	Bristol Myers Squibb
Revlimid	US6555554	Isoindolines, method of use, and pharmaceutical compositions	Jul 24, 2016 (Expired)	Bristol Myers Squibb
Revlimid	US7119106	Pharmaceutical compositions of 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline	Jul 24, 2016 (Expired)	Bristol Myers Squibb
Revlimid	US8288415	Pharmaceutical compositions of 3-(4-amino-1-oxoisoindolin-2yl)-piperidine-2,6-dione	Jul 24, 2016 (Expired)	Bristol Myers Squibb
Revlimid	US8288415	Pharmaceutical compositions of 3-(4-amino-1-oxoisoindolin-2yl)-piperidine-2,6-dione	Jul 24, 2016 (Expired)	Bristol Myers Squibb

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Lenalidomide's patents.

Latest Legal Activities on Lenalidomide's Patents

Given below is the list recent legal activities going on the following patents of Lenalidomide.

Activity	Date	Patent Number

Maintenance Fee Reminder Mailed Critical	11 Mar, 2024	US9393238
Payment of Maintenance Fee, 8th Year, Large Entity	29 Mar, 2023	US9155730
Payment of Maintenance Fee, 8th Year, Large Entity	25 Jan, 2023	US9101622(Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity	25 Jan, 2023	US9101621(Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity	14 Dec, 2022	US7968569(Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity	30 Nov, 2022	US9056120
Payment of Maintenance Fee, 12th Year, Large Entity	08 Jun, 2022	US7855217(Litigated)
Issue Notification Mailed Critical	28 Feb, 2022	US7465800(Litigated)
Court Processing Terminated	28 Feb, 2022	US7465800(Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity	17 Nov, 2021	US8741929

Lenalidomide's Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue

Explore the top-performing drugs that dominate the pharmaceutical industry

View List

NCE-1 Patent Expiry in the Next 1 Year

Identify opportunities as new chemical entity (NCE-1) patents approach expiry

View List

Recently Granted Patents in EP

Find the opportunity to file Oppositions

View List

Lenalidomide Generic API Manufacturers

Several generic applications have been filed for Lenalidomide. The first generic version for Lenalidomide was by Arrow International Ltd and was approved on May 21, 2021. And the latest generic version is by Deva Holding As and was approved on May 22, 2025.

Given below is the list of companies who have filed for Lenalidomide generic, along with the locations of their manufacturing plants worldwide.

1. AMNEAL

Amneal Eu Ltd has filed for 6 different strengths of generic version for Lenalidomide. Given below are the details of the strengths of this generic introduced by Amneal.

Strength	Dosage Form	Availability	Application Pathway	TE code	Launch Date
2.5MG	capsule	Prescription	ORAL	AB	Jan 31, 2025
5MG	capsule	Prescription	ORAL	AB	Jan 31, 2025
10MG	capsule	Prescription	ORAL	AB	Jan 31, 2025
15MG	capsule	Prescription	ORAL	AB	Jan 31, 2025
20MG	capsule	Prescription	ORAL	AB	Jan 31, 2025
25MG	capsule	Prescription	ORAL	AB	Jan 31, 2025

Manufacturing Plant Locations
^New

Amneal's manufacturing plants are situated in 2 countries - United States, India. Given below are the details of these plant locations as well as the firm names of Amneal as present at those locations.

Country

City

Firm Name

United States

Branchburg	Amneal Pharmaceuticals, LLC
Hauppauge	Amneal Pharmaceuticals of New York, LLC
Bridgewater	Amneal Complex Products Research LLC
Glasgow	Amneal Pharmaceuticals LLC
East Hanover	Amneal Pharmaceuticals LLC
Brookhaven	Amneal Pharmaceuticals of New York, LLC
Piscataway	Amneal Pharmaceuticals, LLC
Paterson	Amneal Pharmaceuticals, Llc

India

Ahmedabad	Amneal Pharmaceuticals Private Ltd.
Matoda	Amneal Pharmaceuticals Private Ltd.
Tal Bavla, Ahmedabad	Amneal Pharmaceuticals Pvt. Ltd.
Hyderabad	Amneal Oncology Private Limited

2. APOTEX

Apotex Inc has filed for 6 different strengths of generic version for Lenalidomide. Given below are the details of the strengths of this generic introduced by Apotex.

Strength	Dosage Form	Availability	Application Pathway	TE code	Launch Date
10MG	capsule	Prescription	ORAL	AB	Aug 30, 2022
5MG	capsule	Prescription	ORAL	AB	Aug 30, 2022
25MG	capsule	Prescription	ORAL	AB	Aug 30, 2022
15MG	capsule	Prescription	ORAL	AB	Aug 30, 2022
20MG	capsule	Prescription	ORAL	AB	Mar 7, 2023
2.5MG	capsule	Prescription	ORAL	AB	Mar 7, 2023

Manufacturing Plant Locations
^New

Apotex's manufacturing plants are situated in 3 countries - United States, Canada, India. Given below are the details of these plant locations as well as the firm names of Apotex as present at those locations.

Country

City

Firm Name

United States

Weston

Apotex Corp.

Canada

Toronto	Apotex Inc.
Winnipeg	Apotex Fermentation Inc.
Richmond Hill	Apotex Inc.
Brantford	Apotex Pharmachem Inc.
Etobicoke	Apotex, Inc.
North York	Apotex Inc.

India

Bangalore	Apotex Pharmachem India Pvt Ltd.
Bengaluru	Apotex Research Private Limited
Bangalore	Apotex Research Private Limited - Bioequivalence Centre

3. ARROW INTL

Arrow International Ltd has filed for 6 different strengths of generic version for Lenalidomide. Given below are the details of the strengths of this generic introduced by Arrow Intl.

Strength	Dosage Form	Availability	Application Pathway	TE code	Launch Date
25MG	capsule	Prescription	ORAL	AB	May 21, 2021
15MG	capsule	Prescription	ORAL	AB	May 21, 2021
10MG	capsule	Prescription	ORAL	AB	May 21, 2021
5MG	capsule	Prescription	ORAL	AB	May 21, 2021
2.5MG	capsule	Prescription	ORAL	AB	Mar 6, 2023
20MG	capsule	Prescription	ORAL	AB	Mar 6, 2023

4. BIOCON PHARMA

Biocon Pharma Ltd has filed for 6 different strengths of generic version for Lenalidomide. Given below are the details of the strengths of this generic introduced by Biocon Pharma.

Strength	Dosage Form	Availability	Application Pathway	TE code	Launch Date
2.5MG	capsule	Prescription	ORAL	AB	Mar 3, 2025
25MG	capsule	Prescription	ORAL	AB	Mar 3, 2025
20MG	capsule	Prescription	ORAL	AB	Mar 3, 2025
15MG	capsule	Prescription	ORAL	AB	Mar 3, 2025
10MG	capsule	Prescription	ORAL	AB	Mar 3, 2025
5MG	capsule	Prescription	ORAL	AB	Mar 3, 2025

Manufacturing Plant Locations
^New

Biocon Pharma's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Biocon Pharma as present at those locations.

Country

City

Firm Name

India

Bengaluru

Biocon Pharma Limited

5. CIPLA

Cipla Ltd has filed for 6 different strengths of generic version for Lenalidomide. Given below are the details of the strengths of this generic introduced by Cipla.

Strength	Dosage Form	Availability	Application Pathway	TE code	Launch Date
5MG	capsule	Prescription	ORAL	AB	Sep 6, 2022
10MG	capsule	Prescription	ORAL	AB	Sep 6, 2022
15MG	capsule	Prescription	ORAL	AB	Sep 6, 2022
25MG	capsule	Prescription	ORAL	AB	Sep 6, 2022
20MG	capsule	Prescription	ORAL	AB	Mar 6, 2023
2.5MG	capsule	Prescription	ORAL	AB	Mar 6, 2023

Manufacturing Plant Locations
^New

Cipla's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Cipla as present at those locations.

Country

City

Firm Name

India

Kurkumbh Village, Dist. Pune	Cipla, Ltd.
Bengaluru	Cipla Limited
Pithampur, District Dhar	Cipla Limited
Mumbai	Cipla Limited
Bangalore	Cipla Ltd.
Raigad	Cipla Limited
Vasco Da Gama	Cipla Limited

6. DEVA HOLDING AS

Deva Holding As has filed for 6 different strengths of generic version for Lenalidomide. Given below are the details of the strengths of this generic introduced by Deva Holding As.

Strength	Dosage Form	Availability	Application Pathway	TE code	Launch Date
5MG	capsule	Prescription	ORAL	AB	May 22, 2025
15MG	capsule	Prescription	ORAL	AB	May 22, 2025
20MG	capsule	Prescription	ORAL	AB	May 22, 2025
25MG	capsule	Prescription	ORAL	AB	May 22, 2025
2.5MG	capsule	Prescription	ORAL	AB	May 22, 2025
10MG	capsule	Prescription	ORAL	AB	May 22, 2025

7. DR REDDYS

Dr Reddys Laboratories Ltd has filed for 6 different strengths of generic version for Lenalidomide. Given below are the details of the strengths of this generic introduced by Dr Reddys.

Strength	Dosage Form	Availability	Application Pathway	TE code	Launch Date
2.5MG	capsule	Prescription	ORAL	AB	Oct 14, 2021
20MG	capsule	Prescription	ORAL	AB	Oct 14, 2021
15MG	capsule	Prescription	ORAL	AB	Aug 30, 2022
25MG	capsule	Prescription	ORAL	AB	Aug 30, 2022
5MG	capsule	Prescription	ORAL	AB	Aug 30, 2022
10MG	capsule	Prescription	ORAL	AB	Aug 30, 2022

8. EUGIA PHARMA

Eugia Pharma Specialities Ltd has filed for 6 different strengths of generic version for Lenalidomide. Given below are the details of the strengths of this generic introduced by Eugia Pharma.

Strength	Dosage Form	Availability	Application Pathway	TE code	Launch Date
25MG	capsule	Prescription	ORAL	AB	Mar 6, 2023
2.5MG	capsule	Prescription	ORAL	AB	Mar 6, 2023
5MG	capsule	Prescription	ORAL	AB	Mar 6, 2023
10MG	capsule	Prescription	ORAL	AB	Mar 6, 2023
15MG	capsule	Prescription	ORAL	AB	Mar 6, 2023
20MG	capsule	Prescription	ORAL	AB	Mar 6, 2023

Manufacturing Plant Locations
^New

Eugia Pharma's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Eugia Pharma as present at those locations.

Country

City

Firm Name

India

Medchal-Malkajgiri District	EUGIA Pharma Specialities Limited
Riico Industrial Area	EUGIA Pharma Specialities Limited
Pashamylaram	Eugia Pharma Specialities Limited

9. HETERO LABS LTD V

Hetero Labs Ltd Unit V has filed for 6 different strengths of generic version for Lenalidomide. Given below are the details of the strengths of this generic introduced by Hetero Labs Ltd V.

Strength	Dosage Form	Availability	Application Pathway	TE code	Launch Date
15MG	capsule	Prescription	ORAL	AB	May 11, 2023
10MG	capsule	Prescription	ORAL	AB	May 11, 2023
5MG	capsule	Prescription	ORAL	AB	May 11, 2023
2.5MG	capsule	Prescription	ORAL	AB	May 11, 2023
25MG	capsule	Prescription	ORAL	AB	May 11, 2023
20MG	capsule	Prescription	ORAL	AB	May 11, 2023

10. LOTUS PHARM CO LTD

Lotus Pharmaceutical Co Ltd Nantou Plant has filed for 6 different strengths of generic version for Lenalidomide. Given below are the details of the strengths of this generic introduced by Lotus Pharm Co Ltd.

Strength	Dosage Form	Availability	Application Pathway	TE code	Launch Date
15MG	capsule	Prescription	ORAL	AB	Aug 31, 2022
5MG	capsule	Prescription	ORAL	AB	Aug 31, 2022
10MG	capsule	Prescription	ORAL	AB	Aug 31, 2022
25MG	capsule	Prescription	ORAL	AB	Aug 31, 2022
2.5MG	capsule	Prescription	ORAL	AB	Mar 6, 2023
20MG	capsule	Prescription	ORAL	AB	Mar 6, 2023

11. MYLAN

Mylan Pharmaceuticals Inc has filed for 6 different strengths of generic version for Lenalidomide. Given below are the details of the strengths of this generic introduced by Mylan.

Strength	Dosage Form	Availability	Application Pathway	TE code	Launch Date
25MG	capsule	Prescription	ORAL	AB	Aug 30, 2022
5MG	capsule	Prescription	ORAL	AB	Aug 30, 2022
15MG	capsule	Prescription	ORAL	AB	Aug 30, 2022
10MG	capsule	Prescription	ORAL	AB	Aug 30, 2022
2.5MG	capsule	Prescription	ORAL	AB	Mar 6, 2023
20MG	capsule	Prescription	ORAL	AB	Mar 6, 2023

Manufacturing Plant Locations
^New

Mylan's manufacturing plants are situated in 4 countries - United States, India, Canada, Ireland. Given below are the details of these plant locations as well as the firm names of Mylan as present at those locations.

Country

City

Firm Name

United States

Santa Barbara	Mylandon LLC dba Debbie s Delights Santa Barbara Baking Co.
Greensboro	Mylan Pharmaceuticals Inc
Morgantown	MYLAN CONSUMER HEALTHCARE Inc.
San Carlos	Mylan Pharmaceuticals Inc.
Saint Albans	Mylan Technologies, Inc.
Rockford	Mylan Institutional, Inc.
Morgantown	Mylan Specialty, L.P.

India

Pithampur, District Dhar	Mylan Laboratories Limited
Sinnar	Mylan Laboratories Limited
Aurangabad	Mylan Laboratories Limited (FDF-2)
Sarigam	Mylan Laboratories Limited
Hyderabad	Mylan Laboratories Limited
Anekal Taluk, Bangalore	Mylan Laboratories Limited
Bangalore	Mylan Laboratories Limited
Hosur	Mylan Laboratories Limited

Canada

Etobicoke

Mylan Pharmaceuticals ULC

Ireland

Inverin

Mylan Teoranta

12. NOVUGEN

Novugen Oncology Sdn Bhd has filed for 6 different strengths of generic version for Lenalidomide. Given below are the details of the strengths of this generic introduced by Novugen.

Strength	Dosage Form	Availability	Application Pathway	TE code	Launch Date
15MG	capsule	Prescription	ORAL	AB	Sep 11, 2024
2.5MG	capsule	Prescription	ORAL	AB	Sep 11, 2024
25MG	capsule	Prescription	ORAL	AB	Sep 11, 2024
20MG	capsule	Prescription	ORAL	AB	Sep 11, 2024
5MG	capsule	Prescription	ORAL	AB	Sep 11, 2024
10MG	capsule	Prescription	ORAL	AB	Sep 11, 2024

13. QILU

Qilu Pharmaceutical Co Ltd has filed for 6 different strengths of generic version for Lenalidomide. Given below are the details of the strengths of this generic introduced by Qilu.

Strength	Dosage Form	Availability	Application Pathway	TE code	Launch Date
25MG	capsule	Discontinued	ORAL	N/A	Feb 22, 2024
2.5MG	capsule	Discontinued	ORAL	N/A	Feb 22, 2024
15MG	capsule	Discontinued	ORAL	N/A	Feb 22, 2024
10MG	capsule	Discontinued	ORAL	N/A	Feb 22, 2024
5MG	capsule	Discontinued	ORAL	N/A	Feb 22, 2024
20MG	capsule	Discontinued	ORAL	N/A	Feb 22, 2024

Manufacturing Plant Locations
^New

Qilu's manufacturing plants are situated in 1 country - China. Given below are the details of these plant locations as well as the firm names of Qilu as present at those locations.

Country

City

Firm Name

China

Haikou	Qilu Pharmaceutical (Hainan) Co. Ltd.
Jinan	Qilu Antibiotics Pharmaceutical Co. , Ltd.
Hulunbeier	Qilu Pharmaceutical Hulun Buir Branch
Hohhot	Qilu Pharmaceutical (Inner Mongolia) Co., Ltd.
Jinan	Qilu Pharmaceutical Co., Ltd. (High Tech Zone Site)
Dezhou	Qilu SYNVA Pharmaceutical Co. Ltd
Jinan	Qilu Pharmaceutical Co., Ltd.

14. SUN PHARM

Sun Pharmaceutical Industries Ltd has filed for 6 different strengths of generic version for Lenalidomide. Given below are the details of the strengths of this generic introduced by Sun Pharm.

Strength	Dosage Form	Availability	Application Pathway	TE code	Launch Date
5MG	capsule	Prescription	ORAL	AB	Feb 8, 2023
15MG	capsule	Prescription	ORAL	AB	Feb 8, 2023
10MG	capsule	Prescription	ORAL	AB	Feb 8, 2023
25MG	capsule	Prescription	ORAL	AB	Feb 8, 2023
2.5MG	capsule	Prescription	ORAL	AB	Mar 6, 2023
20MG	capsule	Prescription	ORAL	AB	Mar 6, 2023

Manufacturing Plant Locations
^New

Sun Pharm's manufacturing plants are situated in 2 countries - United States, India. Given below are the details of these plant locations as well as the firm names of Sun Pharm as present at those locations.

Country

City

Firm Name

United States

Lexington	Sun Pharmaceutical Industries Inc
Princeton	SUN PHARMACEUTICAL INDUSTRIES INC
Billerica	Sun Pharmaceutical Industries, Inc.

India

Punjab	Sun Pharmaceutical Industries, Inc.
Kanchipuram	Sun Pharmaceutical Industries Limited- Madhuranthagam
Vadodara	Sun Pharmaceutical Industries Ltd
Malanpur, Bhind (District)	Sun Pharmaceutical Industries Limited
Halol	Sun Pharmaceutical Industries Ltd.
Dadra	Sun Pharmaceutical Industries Limited
Vadodara	Sun Pharmaceutical Industries Limited - Karkhadi
Gurugram	Sun Pharmaceutical Industries Limited (prev. Ranbaxy)
Vadodara	Sun Pharmaceutical Industries Ltd.
Baruch	Sun Pharmaceutical Industries Ltd.
Mohali	Sun Pharmaceutical Industries Limited
New Delhi	Sun Pharmaceutical Industries Limited
Bharuch	Sun Pharmaceutical Industries Ltd
Ahmednagar	Sun Pharmaceutical Industries Limited

15. TORRENT

Torrent Pharmaceuticals Ltd has filed for 3 different strengths of generic version for Lenalidomide. Given below are the details of the strengths of this generic introduced by Torrent.

Strength	Dosage Form	Availability	Application Pathway	TE code	Launch Date
10MG	capsule	Discontinued	ORAL	N/A	Feb 17, 2023
25MG	capsule	Discontinued	ORAL	N/A	Feb 17, 2023
20MG	capsule	Discontinued	ORAL	N/A	Aug 3, 2023

Manufacturing Plant Locations
^New

Torrent's manufacturing plants are situated in 2 countries - India, United States. Given below are the details of these plant locations as well as the firm names of Torrent as present at those locations.

Country

City

Firm Name

India

Bharuch	Torrent Pharmaceuticals Limited
Indrad	Torrent Pharmaceuticals Limited
Pithampur	Torrent Pharmaceuticals Limited
Thanam	Torrent Pharmaceuticals Limited
Gandhi Nagar	Torrent Pharmaceuticals Limited

United States

Basking Ridge	Torrent Pharma Inc.
Kalamazoo	Torrent Pharma Inc.

16. ZYDUS PHARMS

Zydus Pharmaceuticals Usa Inc has filed for 6 different strengths of generic version for Lenalidomide. Given below are the details of the strengths of this generic introduced by Zydus Pharms.

Strength	Dosage Form	Availability	Application Pathway	TE code	Launch Date
5MG	capsule	Prescription	ORAL	AB	Sep 12, 2022
25MG	capsule	Prescription	ORAL	AB	Sep 12, 2022
15MG	capsule	Prescription	ORAL	AB	Sep 12, 2022
10MG	capsule	Prescription	ORAL	AB	Sep 12, 2022
2.5MG	capsule	Prescription	ORAL	AB	Mar 6, 2023
20MG	capsule	Prescription	ORAL	AB	Mar 6, 2023

Pharsight

Pharsight

Lenalidomide Patent Expiration

Lenalidomide Patents

Latest Legal Activities on Lenalidomide's Patents

Lenalidomide's Family Patents

Explore Our Curated Drug Screens

Lenalidomide Generic API Manufacturers

1. AMNEAL

Manufacturing Plant Locations
^New

2. APOTEX

Manufacturing Plant Locations
^New

3. ARROW INTL

4. BIOCON PHARMA

Manufacturing Plant Locations
^New

5. CIPLA

Manufacturing Plant Locations
^New

6. DEVA HOLDING AS

7. DR REDDYS

8. EUGIA PHARMA

Manufacturing Plant Locations
^New

9. HETERO LABS LTD V

10. LOTUS PHARM CO LTD

11. MYLAN

Manufacturing Plant Locations
^New

12. NOVUGEN

13. QILU

Manufacturing Plant Locations
^New

14. SUN PHARM

Manufacturing Plant Locations
^New

15. TORRENT

Manufacturing Plant Locations
^New

16. ZYDUS PHARMS

Lenalidomide News

Have Questions?

Pharsight

Pharsight

Lenalidomide Patents

Latest Legal Activities on Lenalidomide's Patents

Lenalidomide's Family Patents

Explore Our Curated Drug Screens

Lenalidomide Generic API Manufacturers

1. AMNEAL

Manufacturing Plant Locations New

2. APOTEX

Manufacturing Plant Locations New

3. ARROW INTL

4. BIOCON PHARMA

Manufacturing Plant Locations New

5. CIPLA

Manufacturing Plant Locations New

6. DEVA HOLDING AS

7. DR REDDYS

8. EUGIA PHARMA

Manufacturing Plant Locations New

9. HETERO LABS LTD V

10. LOTUS PHARM CO LTD

11. MYLAN

Manufacturing Plant Locations New

12. NOVUGEN

13. QILU

Manufacturing Plant Locations New

14. SUN PHARM

Manufacturing Plant Locations New

15. TORRENT

Manufacturing Plant Locations New

16. ZYDUS PHARMS

Lenalidomide News

Related content

Have Questions?

Manufacturing Plant Locations
^New

Manufacturing Plant Locations
^New

Manufacturing Plant Locations
^New

Manufacturing Plant Locations
^New

Manufacturing Plant Locations
^New

Manufacturing Plant Locations
^New

Manufacturing Plant Locations
^New

Manufacturing Plant Locations
^New

Manufacturing Plant Locations
^New